Project Grant R01HL179825
Award Date 7/25/26
Completion Date 3/31/30
Dollars Obligated $703K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Tallahassee, FL 32306, USA
Similar Awards
- The National Institutes of Health National Heart, Lung, and Blood Institute awarded the University of Arizona $650,419 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate how myosin and cardiac thin filament mutations cause allosteric dysfunction in hypertrophic cardiomyopathy. The research extends a program studying sarcomere function in health and disease. The project develops coupled time-resolved FRET computation-based methods to characterize...
- The National Heart, Lung, and Blood Institute awarded the University of Virginia $248,999 on August 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms regulating T-tubule structure in the mammalian heart during mechanical load conditions. The research will employ novel magnetorheological elastomer culture systems to subject isolated cardiomyocytes to pathological overload while comprehensively characterizing excitation-contraction...
- The National Heart, Lung, and Blood Institute awarded Old Dominion University $1,630,808 on July 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate mechanisms of thin filament regulation by cardiac myosin-binding protein C in health and disease. The award funds research on how mutations in MYBPC3, the gene encoding cardiac myosin-binding protein C (cMyBP-C), contribute to familial hypertrophic cardiomyopathy in over 40 percent of patients. cMyBP-C...
- The National Heart, Lung, and Blood Institute awarded Case Western Reserve University $4,349,952 on July 15, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the phosphorylation-based molecular and functional mechanisms by which cardiac myosin binding protein C (CMYBP-C) modulates cardiac contractile function. The research employs a multidisciplinary experimental approach spanning atomic to whole-organ scales to determine how CMYBP-C conformational changes in...
- The National Institute of General Medical Sciences awarded The Leland Stanford Junior University $494,796 on March 1, 2026, to investigate myosin structure and function in hereditary cardiac disease, specifically familial hypertrophic cardiomyopathy (HCM). The award funds research into how mutations in cardiac myosin and myosin binding protein C—which account for approximately 90 percent of HCM cases—disrupt the biochemical and biomechanical function of the myosin motor, leading to cardiac...
- The National Heart, Lung, and Blood Institute awarded the University of Arizona $562,733 on July 6, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop small molecule therapeutics for heart failure through reduction in tristetraprolin activity and improvement of cardiac metabolism. The project runs through May 31, 2027, with work performed in Tucson, Arizona. The research targets tristetraprolin, a zinc finger protein that regulates fatty acid uptake and oxidation...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $150,104 on September 30, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate TRAPPC11 as a therapeutic target for inherited dilated cardiomyopathy. The funded research will evaluate TRAPPC11 inhibition as a potential treatment for dilated cardiomyopathy caused by TNNT2 mutations and other forms of the disease. The investigator will conduct knockdown studies in a mouse...
- The National Heart, Lung, and Blood Institute awarded The Leland Stanford Junior University $198,728 on March 1, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate the molecular mechanisms of mitochondrial calcium extrusion in ischemic heart disease. The research focuses on TMEM65, an emerging target implicated in mitochondrial sodium-dependent calcium extrusion (MNCX). Ischemia-reperfusion injury damages cardiac tissue partly through aberrant mitochondrial...
- The National Institutes of Health National Heart Lung and Blood Institute awarded Case Western Reserve University $128,916 on December 12, 2025, under the Cardiovascular Diseases Research program (CFDA 93.837) to investigate chronic myosin activation as an agonist of cardiac mechanosensory pathways. The research examines long-term cardiac effects of myosin activators, specifically danicamtiv, a next-generation therapeutic in clinical trials for heart failure with reduced ejection fraction....
- The National Heart, Lung, and Blood Institute awarded the University of California, San Diego $795,900 on August 25, 2026, under the Cardiovascular Diseases Research program (CFDA 93.837) to develop gene therapy for FLNC haploinsufficiency cardiomyopathy. FLNC haploinsufficiency, caused by nonsense, frameshift, or splice-site mutations, drives inherited dilated and arrhythmogenic cardiomyopathies characterized by early-onset systolic dysfunction, high malignant arrhythmia risk, and sudden...